12/12/19 12:21 PM H.R. 3
On agreeing to the Finkenauer amendment; Agreed to by voice vote.
12/12/19 12:13 PM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Finkenauer amendment No. 9.
12/12/19 12:13 PM H.R. 3
Amendment offered by Ms. Finkenauer.
12/12/19 12:13 PM H.R. 3
An amendment, offered by Ms. Finkenauer, numbered 9 printed in Part B of House Report 116-334 to require drug companies to disclose truthful and non-misleading pricing information about prescription drugs and biological products when they advertise these products directly to consumers.
12/12/19 12:12 PM H.R. 3
On agreeing to the Axne amendment; Agreed to by voice vote.
12/12/19 12:05 PM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Axne amendment No. 8.
12/12/19 12:05 PM H.R. 3
An amendment, offered by Mrs. Axne, numbered 8 printed in Part B of House Report 116-334 to establish a grant program for states to reduce the burdens associated with health care administrative work and reduces HHS administrative costs by 50% over 10 years.
12/12/19 12:04 PM H.R. 3
POSTPONED PROCEEDINGS - At the conclusion of debate on the Gottheimer amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the ayes had prevailed. Mr. Gottheimer demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
12/12/19 11:54 AM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Gottheimer amendment No. 7.
12/12/19 11:54 AM H.R. 3
An amendment, offered by Mr. Gottheimer, numbered 7 printed in Part B of House Report 116-334 to require an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease. Requires HHS to identify appropriate incentives that would lead to the development of such treatments.
